Dr.  Schaeffer is an active member of the American Urology Association (AUA), North-Central section of the AUA, the Society of Urologic Oncology and the American Society of Clinical Oncology.  He has been an invited speaker at multiple international conferences and review courses.

He is on the Board of Directors of the Society of Urologic Oncology – Clinical Trials consortium.   He serves as a panel member of the National Comprehensive Cancer Network Prostate Cancer guideline committee, a group that serves to develop internationally recognized treatment recommendations for prostate cancer and he is on the ASCO (American Society for Clinical Oncology) meeting steering committee.   Additionally, Dr. Schaeffer directs the ECOG (Eastern Cooperative Oncology Group) Genito-Urinary early modality group – a committee that directs and focuses ECOG investigators developing clinical trials in the surgical and pre-surgical space.

He is a reviewer for numerous highly regarded journals and is on the editorial board of the Journal of Urology – the field’s oldest and most regarded publication.  In this capacity he acts a Urology survey editor whereby he systematically reviews publications in the field of Urology and writes a summary of them for the Journal of Urology readership.  The “Urology survey” is one of the most highly read sections of the Journal and Dr. Schaeffer’s contribution to it reflect his understanding of the literature and international recognition.  He also acts as an associate editor for “Case Reports in Urology”.  

He is the founder and chief medical officer of the Prostate Cancer Foundation of Norway and in this capacity he oversees the mission and scientific activities of the foundation including patient and physician knowledge transfer and support of Norwegian prostate cancer research.  He is on the Board of Directors of the Society of Urologic Oncology – Clinical Trials consortium.   He serves as a panel member of the National Comprehensive Cancer Network Prostate Cancer guideline committee, a group that serves to develop internationally recognized treatment recommendations for prostate cancer and he is on the ASCO (American Society for Clinical Oncology) meeting steering committee.

Additionally, Dean Eric Neilson appointed him the first Edmund Andrews Professor of Urology.